Augmentation of chemotherapeutic infusion effect by TSU-68, an oral targeted antiangiogenic agent, in a rabbit vx2 liver tumor model

CardioVascular and Interventional Radiology

Volumn 35, Issue 1, 2012, Pages 168-175

  Kim, Hyo Cheol ^a   Chung, Jin Wook ^a   Choi, Seung Hong ^a   Im, Seock Ah ^a   Yamasaki, Yasundo ^b   Jun, Suryoung ^a   Jae, Hwan Jun ^a   Park, Jae Hyung ^a  

^a Seoul National University Hospital   (South Korea)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Angiogenesis inhibitor; Chemoembolization; Combined therapy; Hepatocellular carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARBOXYMETHYLCELLULOSE; ORANTINIB; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD VESSEL PARAMETERS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SIZE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EXPERIMENTAL RABBIT; LIVER CARCINOMA; MICROSCOPY; MICROVESSEL DENSITY; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG THERAPY, COMBINATION; ETHIODIZED OIL; INDOLES; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROPIONIC ACIDS; RABBITS; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84857057962     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-010-0081-y     Document Type: Article

References (25)

1. DM Parkin F Bray J Ferlay P Pisani 2001 Estimating the world cancer burden: Globocan 2000 Int J Cancer 94 153 156 11668491 10.1002/ijc.1440 1:CAS:528:DC%2BD3MXntVGlu78%3D (Pubitemid 32911406)
2. A Forner ME Reig CR de Lope J Bruix 2010 Current strategy for staging and treatment: the BCLC update and future prospects Semin Liver Dis 30 61 74 20175034 10.1055/s-0030-1247133 1:CAS:528:DC%2BC3cXjvFCqtbY%3D
3. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 18650514 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D
4. AL Cheng YK Kang Z Chen, et al. 2009 Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial Lancet Oncol 10 25 34 19095497 10.1016/S1470-2045(08)70285-7 1:CAS:528:DC%2BD1cXhsFChtbnM
5. AD Laird P Vajkoczy LK Shawver, et al. 2000 SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Res 60 4152 4160 10945623 1:CAS:528:DC%2BD3cXlvFOkt7s%3D (Pubitemid 30636598)
6. E Naumova P Ubezio A Garofalo, et al. 2006 The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis Clin Cancer Res 12 1839 1849 16551869 10.1158/1078-0432.CCR-05-1615 1:CAS:528:DC%2BD28Xis1CjsLc%3D
7. P Marzola A Degrassi L Calderan, et al. 2004 In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model Clin Cancer Res 10 739 750 14760097 10.1158/1078-0432.CCR-0828-03 1:CAS:528:DC%2BD2cXovVKisg%3D%3D (Pubitemid 38174012)
8. AD Laird JG Christensen G Li, et al. 2002 SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice FASEB J 16 681 690 11978732 1:CAS:528:DC%2BD38XjsVChu7w%3D (Pubitemid 34465432)
9. A Garofalo E Naumova L Manenti, et al. 2003 The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically Clin Cancer Res 9 3476 3485 12960140 1:CAS:528: DC%2BD3sXotFCkt7w%3D (Pubitemid 37082747)
10. Kanai F, Yoshida H, Tateishi R et al (2010) A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol, published online April
11. JM Llovet J Bruix 2003 Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 429 442 12540794 10.1053/jhep.2003.50047 1:CAS:528: DC%2BD3sXhsFeltrg%3D (Pubitemid 36152543)
12. J Bruix M Sala JM Llovet 2004 Chemoembolization for hepatocellular carcinoma Gastroenterology 127 S179 S188 15508083 10.1053/j.gastro.2004.09.032 1:CAS:528:DC%2BD2cXhtVGmtb%2FF (Pubitemid 39423386)
13. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
14. K Yorozuya T Kubota M Watanabe, et al. 2005 TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis Oncol Rep 14 677 682 16077974 1:CAS:528:DC%2BD2MXpvFGjsrc%3D
15. M Yamamoto H Kikuchi M Ohta, et al. 2008 TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche Cancer Res 68 9754 9762 19047154 10.1158/0008-5472.CAN-08-1748 1:CAS:528:DC%2BD1cXhsVegtbjM
16. Q Zhou M Olivo KY Lye S Moore A Sharma B Chowbay 2005 Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models Cancer Chemother Pharmacol 56 569 577 16001166 10.1007/s00280-005-1017-0 1:CAS:528:DC%2BD2MXhtVKqu7bJ (Pubitemid 41425052)
17. S Machida Y Saga Y Takei, et al. 2005 Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68) Int J Cancer 114 224 229 15551349 10.1002/ijc.20751 1:CAS:528:DC%2BD2MXhtFOlu7Y%3D (Pubitemid 40194290)
18. FM Klenke A Abdollahi E Bertl, et al. 2007 Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo BMC Cancer 7 49 17367541 10.1186/1471-2407-7-49 (Pubitemid 46502378)
19. Murakami H, Ueda Y, Shimoyama T et al (2010) Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer Chemother Pharmacol, published online July
20. Ueda Y, Shimoyama T, Murakami H et al (2010) Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemother Pharmacol, published online July
21. H Huynh 2010 Tyrosine kinase inhibitors to treat liver cancer Expert Opin Emerg Drugs 15 13 26 20128706 10.1517/14728210903571659 1:CAS:528: DC%2BC3cXivFels74%3D
22. RK Jain RT Tong LL Munn 2007 Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model Cancer Res 67 2729 2735 17363594 10.1158/0008-5472.CAN-06-4102 1:CAS:528:DC%2BD2sXivV2nsLw%3D (Pubitemid 46548961)
23. M Ohta T Kawabata M Yamamoto, et al. 2009 TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model Surg Today 39 1046 1053 19997799 10.1007/s00595-009-4020-y 1:CAS:528:DC%2BD1MXhsFanu7fN
24. H Jiang Q Meng H Tan, et al. 2007 Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas Int J Cancer 121 416 424 17330237 10.1002/ijc.22655 1:CAS:528: DC%2BD2sXmslOltLo%3D (Pubitemid 46917712)
25. A Riaz FH Miller LM Kulik, et al. 2010 Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma JAMA 303 1062 1069 20233824 10.1001/jama.2010.262 1:CAS:528:DC%2BC3cXjsF2qs7k%3D